AstraZeneca PLC (GB:AZN)
LSE:AZN
Holding GB:AZN?
Track your performance easily

AstraZeneca (AZN) Share Forecast & Price Target

490 Followers
See the Price Targets and Ratings of:

AZN Analyst Ratings

Moderate Buy
15Ratings
10 Buy
2 Hold
3 Sell
Based on 15 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

13,705.66p
▲(38.48% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is 13,705.66p with a high forecast of 20,000.00p and a low forecast of 10,500.00p. The average price target represents a 38.48% change from the last price of 9,897.50p.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9978":"9,978p","20001":"20,001p","12483.75":"12,483.8p","14989.5":"14,989.5p","17495.25":"17,495.3p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13705.66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">14K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9978,12483.75,14989.5,17495.25,20001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11022,11712.615384615385,12403.23076923077,13093.846153846154,13784.461538461539,14475.076923076924,15165.692307692309,15856.307692307691,16546.923076923078,17237.53846153846,17928.153846153848,18618.76923076923,19309.384615384617,{"y":20000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11022,11228.435384615384,11434.870769230769,11641.306153846153,11847.741538461538,12054.176923076922,12260.612307692307,12467.047692307693,12673.483076923078,12879.918461538462,13086.353846153846,13292.789230769231,13499.224615384615,{"y":13705.66,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11022,10981.846153846154,10941.692307692309,10901.538461538461,10861.384615384615,10821.23076923077,10781.076923076924,10740.923076923076,10700.76923076923,10660.615384615385,10620.461538461539,10580.307692307691,10540.153846153846,{"y":10500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10049.57,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9979.12,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10527.1,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10137.64,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10018.36,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10555.06,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11976.31,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12479.22,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11982.28,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12532.89,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12650,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11738,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11022,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target20,000pAverage Price Target13,706pLowest Price Target10,500p
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein
20,000p
Buy
102.07%
Upside
Reiterated
09/11/24
AstraZeneca Buy Rating Affirmed: Anticipated FDA Approval of Dato and Long-Term Growth Potential
Nordea Markets
10,873.17p
Sell
9.86%
Upside
Downgraded
09/11/24
AstraZeneca downgraded to Sell from Hold at NordeaAstraZeneca downgraded to Sell from Hold at Nordea
Kepler Capital
11,300p
Hold
14.17%
Upside
Reiterated
09/10/24
Kepler Capital Sticks to Their Hold Rating for AstraZeneca (AZN)
TD Cowen
14,860p
Buy
50.14%
Upside
Reiterated
08/11/24
We took another look at our AZN model as we approach the midpoint of Q3. We raised estimates in each year through 2030, reflecting growth that is above the industry average, yet we still are below management's 2030 revenue target. All told, AZN appears to have much business momentum and news upcoming, and as such we rate the stock Buy.
DZ BANK AG
Hold
Reiterated
07/26/24
AstraZeneca (AZN) Receives a Hold from DZ BANK AG

Best Analysts Covering AstraZeneca

Which Analyst Should I Follow If I Want to Buy GB:AZN and Sell After:
1 Month
xxx
Success Rate
34/55 ratings generated profit
62%
Average Return
+1.52%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.82% of your transactions generating a profit, with an average return of +1.52% per trade.
3 Months
xxx
Success Rate
36/55 ratings generated profit
65%
Average Return
+5.61%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 65.45% of your transactions generating a profit, with an average return of +5.61% per trade.
1 Year
Success Rate
28/29 ratings generated profit
97%
Average Return
+16.98%
reiterated a sell rating 4 days ago
Copying Matthew Weston's trades and holding each position for 1 Year would result in 96.55% of your transactions generating a profit, with an average return of +16.98% per trade.
2 Years
xxx
Success Rate
28/29 ratings generated profit
97%
Average Return
+26.59%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 96.55% of your transactions generating a profit, with an average return of +26.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
0
0
1
1
1
Buy
38
28
34
23
26
Hold
11
9
9
5
4
Sell
3
2
3
2
2
Strong Sell
1
1
3
3
4
total
53
40
50
34
37
In the current month, AZN has received 27 Buy Ratings, 4 Hold Ratings, and 6 Sell Ratings. AZN average Analyst price target in the past 3 months is 13,705.66p.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is 1.58p with a range of 1.47p to 1.73p. The previous quarter’s EPS was 1.53p. AZN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.00% of the time in the same period. In the last calendar year AZN has Outperformed its overall industry.
Next quarter’s earnings estimate for AZN is 1.58p with a range of 1.47p to 1.73p. The previous quarter’s EPS was 1.53p. AZN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.00% of the time in the same period. In the last calendar year AZN has Outperformed its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is 10.09B with a range of 9.64B to 10.29B. The previous quarter’s sales results were 10.25B. AZN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 44.74% of the time in the same period. In the last calendar year AZN has Outperformed its overall industry.
Next quarter’s sales forecast for AZN is 10.09B with a range of 9.64B to 10.29B. The previous quarter’s sales results were 10.25B. AZN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 44.74% of the time in the same period. In the last calendar year AZN has Outperformed its overall industry.

AZN Stock Forecast FAQ

What is GB:AZN’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 13,705.66p.
    What is GB:AZN’s upside potential, based on the analysts’ average price target?
    AstraZeneca PLC has 38.48% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AstraZeneca PLC a Buy, Sell or Hold?
          AstraZeneca PLC has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 2 hold ratings and 3 sell ratings.
            What is AstraZeneca PLC’s share price target?
            The average share price target for AstraZeneca PLC is 13,705.66p. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is 20,000.00p ,and the lowest forecast is 10,500.00p. The average share price target represents 38.48% Increase from the current price of 9,897.5p.
              What do analysts say about AstraZeneca PLC?
              AstraZeneca PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of AstraZeneca PLC?
                To buy shares of GB:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis